On Wednesday, Shares of Rite Aid Corporation (NYSE:RAD), lost -1.19% to $8.72.
Rite Aid Corporation, declared that seasonal flu shots are now accessible at all Rite Aid pharmacies nationwide. Customers can visit any of Rite Aid’s nearly 4,600 pharmacies to receive a flu shot from a certified immunizing Rite Aid pharmacist, subject to state regulations. Flu shots are covered by most insurance plans, counting Medicare Part B and are accessible during pharmacy hours; no appointment is necessary.
“While the timing of flu season is unpredictable, outbreaks can happen as early as October, which is why it is so important to get vaccinated as early as possible,” said Jocelyn Konrad, Rite Aid executive vice president of pharmacy. “Rite Aid encourages people to get a flu shot sooner rather than later, as it is the very best way to protect themselves and their loved ones from getting the flu.”
Rite Aid carries the standard trivalent flu vaccine, which offers protection against three strains of the flu: the influenza A H3N2 virus, the influenza B virus and the influenza A H1N1. Additionally, a quadrivalent flu vaccine that offers protection against an additional influenza B virus will also be accessible. The Centers for Disease Control and Prevention (CDC) recommends that everyone six months and older get a flu vaccination as soon as it is accessible, since it takes about two weeks after vaccination for antibodies to develop in the body and provide protection against the flu.
Rite Aid Corporation, through its auxiliaries, operates a chain of retail drugstores in the United States. The company sells prescription drugs and a range of other merchandise, counting over-the-counter medications, health and beauty aids, personal care items, cosmetics, household items, food and beverages, greeting cards, seasonal merchandise, and other every day and convenience products.
Shares of Solera Holdings Inc (NYSE:SLH), inclined 0.31% to $48.65, during its last trading session.
Solera Holdings Inc, which provides technology services to insurance companies, is in advanced talks to sell itself to private equity firms, according to a person familiar with the matter.
Earlier, Bloomberg News stated that Solera had approached buyout firms counting Pamplona Capital Administration and Thoma Bravo LLC about a possible sale.
Solera, founded in 2005, has a market capitalization of $3.25 billion and assists insurers process claims. Solera’s website says the company’s clients comprise the 10 largest insurance companies in Europe and the United States.
Solera Holdings, Inc. provides software and services to insurance companies, collision repair facilities, independent assessors, automotive recyclers, auto dealers, and households.
Finally, Lannett Company, Inc (NYSE:LCI), ended its last trade with -0.92% loss, and closed at $51.93.
declared that its Silarx Pharmaceuticals, Inc. partner has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Aripiprazole Oral Solution 1 mg/mL, the generic version of the antidepressant drug ABILIFY®. According to IMS, annual total sales of Aripiprazole 1 mg/ml Oral Solution at Average Wholesale Price (AWP) were about $76 million. The FDA website reports certain formulations of ABILIFY®, counting the oral solution 1 mg/mL dosage, have been suspended by the brand manufacturer.
“Our generic Aripiprazole 1 mg/ml Oral Solution product is one of two to be approved by FDA; shipping of this important medication has commenced,” said Arthur Bedrosian, chief executive officer of Lannett. “This approval is the first from our recently accomplished acquisition of Silarx.”
Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of branded pharmaceutical products in the United States. It offers solid oral, extended release, topical, and oral solution finished dosage forms of drugs that address a range of therapeutic areas.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
